Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Myelofibrosis
Related studies linked through entity extraction aliases.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Status
- RECRUITING
- Phase
- N/A
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
- Status
- WITHDRAWN
- Phase
- PHASE2
Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.
- Status
- COMPLETED
- Phase
- PHASE2
Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
- Status
- TERMINATED
- Phase
- PHASE1
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Status
- RECRUITING
- Phase
- PHASE2
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
- Status
- RECRUITING
- Phase
- N/A
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
- Status
- COMPLETED
- Phase
- PHASE1
Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis
- Status
- COMPLETED
- Phase
- N/A
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
- Status
- TERMINATED
- Phase
- PHASE2
PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE2
Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
- Status
- TERMINATED
- Phase
- PHASE2